{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:19Z","timestamp":1786115059919,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013446","name":"Alabama Humanities Alliance","doi-asserted-by":"publisher","award":["23CDA1042602"],"award-info":[{"award-number":["23CDA1042602"]}],"id":[{"id":"10.13039\/100013446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT2OD032581-01"],"award-info":[{"award-number":["1OT2OD032581-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018647","name":"John T. Milliken Department of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["AHA 23CDA1042602"],"award-info":[{"award-number":["AHA 23CDA1042602"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K23HL171636"],"award-info":[{"award-number":["K23HL171636"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.03.015","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:17:14Z","timestamp":1776874634000},"page":"596-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial Disparities in SGLT2 Inhibitor Initiation Among Medicaid-Insured Adults With Type 2 Diabetes: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Vivian Hsing-Chun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdul","family":"Sabboor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rajbhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4721","authenticated-orcid":false,"given":"Donglan S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.aed.2026.03.015_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2337\/dc14-2334","article-title":"Surge in newly identified diabetes among medicaid patients in 2014 within medicaid expansion states under the affordable care act","volume":"38","author":"Kaufman","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.aed.2026.03.015_bib2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1377\/hlthaff.24.4.1073","article-title":"Assessing access to care under medicaid: evidence for the nation and thirteen states","volume":"24","author":"Coughlin","year":"2005","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl 1","key":"10.1016\/j.aed.2026.03.015_bib3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc23-Srev","article-title":"Summary of revisions: standards of care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.aed.2026.03.015_bib4","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.aed.2026.03.015_bib5","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.aed.2026.03.015_bib6","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.aed.2026.03.015_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-Pocket costs for SGLT-2 (Sodium-Glucose transport Protein-2) inhibitors in the United States","volume":"15","author":"Aggarwal","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.aed.2026.03.015_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aed.2026.03.015_bib9","article-title":"Evidence-based practice in prescribing SGLT2i and GLP-1 RA across ethnic and racial groups: a systematic review and meta-analysis of observational studies","author":"Ananthesh","year":"2025","journal-title":"J Racial Ethn Health Disparities"},{"issue":"4, Supplement","key":"10.1016\/j.aed.2026.03.015_bib10","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.jacl.2024.04.043","article-title":"Racial variations in SGLT2 inhibitor prescriptions","volume":"18","author":"Leung","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.aed.2026.03.015_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21878-x","article-title":"Racial disparities and prevalence of cardiovascular disease risk factors, cardiometabolic risk factors, and cardiovascular health metrics among US adults: NHANES 2011\u20132018","volume":"12","author":"Lopez-Neyman","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.aed.2026.03.015_bib12","series-title":"Encyclopedia of Biostatistics [Internet]","article-title":"Nelson\u2013Aalen estimator","author":"Borgan","year":"2005"},{"key":"10.1016\/j.aed.2026.03.015_bib13","article-title":"Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"34","author":"Rodriguez","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"10.1016\/j.aed.2026.03.015_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health administration system","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.aed.2026.03.015_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s13300-025-01793-w","article-title":"Therapeutic inertia in an insured population with type 2 diabetes in the United States: a retrospective cohort study","volume":"16","author":"Boye","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.aed.2026.03.015_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221081601","article-title":"Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future","volume":"13","author":"Mallik","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.aed.2026.03.015_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.18553\/jmcp.2025.31.2.214","article-title":"Pharmacoequity measurement framework: a tool to reduce health disparities","volume":"31","author":"Patel","year":"2025","journal-title":"JMCP"},{"issue":"12","key":"10.1016\/j.aed.2026.03.015_bib18","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1377\/hlthaff.2017.0925","article-title":"The effect of medicaid on medication use among poor adults: evidence from Oregon","volume":"36","author":"Baicker","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"12","key":"10.1016\/j.aed.2026.03.015_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"7","key":"10.1016\/j.aed.2026.03.015_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/ajhp\/zxy083","article-title":"Understanding the medication prior-authorization process: a case study of patients and clinical staff from a large rural integrated health delivery system","volume":"76","author":"Jones","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.aed.2026.03.015_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s13300-024-01530-9","article-title":"Therapeutic inertia in the management of type 2 diabetes: a narrative review","volume":"15","author":"Rodriguez","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.aed.2026.03.015_bib22","article-title":"Diabetes medication prescribing trends based on provider type and location in the United States","volume":"49","author":"Meeke","year":"2025","journal-title":"Prev Med Rep"},{"issue":"2","key":"10.1016\/j.aed.2026.03.015_bib23","first-page":"46","article-title":"Factors and disparities influencing sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists initiation in the United States: a scoping review of evidence","volume":"13","author":"Moore","year":"2025","journal-title":"Pharmacy (Basel)"},{"issue":"2","key":"10.1016\/j.aed.2026.03.015_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/cd23-0048","article-title":"Implicit or unconscious bias in diabetes care","volume":"42","author":"Caballero","year":"2024","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.1016\/j.aed.2026.03.015_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.2329","article-title":"Prescription drug utilization and spending by race, ethnicity, payer, health condition, and US state","volume":"6","author":"Sahu","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"9","key":"10.1016\/j.aed.2026.03.015_bib26","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11606-024-08638-5","article-title":"Racial and ethnic disparities in the prescribing of pain medication in US primary care settings, 1999-2019: where are we now?","volume":"39","author":"Thompson","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"9","key":"10.1016\/j.aed.2026.03.015_bib27","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.2337\/dc05-1973","article-title":"Disparities in HbA1c levels between African-American and Non-Hispanic white adults with diabetes: a meta-analysis","volume":"29","author":"Kirk","year":"2006","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.aed.2026.03.015_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36307","article-title":"Racial and ethnic disparities in glycemic control among insured US adults","volume":"6","author":"Zakaria","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:19:47Z","timestamp":1785975587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000779"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.015","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial Disparities in SGLT2 Inhibitor Initiation Among Medicaid-Insured Adults With Type 2 Diabetes: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}